4.5 Review

Characterization of the dystrophin-associated protein complex by mass spectrometry

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy

Vahid Farrokhi et al.

Summary: Duchenne muscular dystrophy (DMD) is a degenerative muscle disorder caused by mutations in the DMD gene, and gene therapy strategies aiming to increase expression of functional mini-dystrophin protein are being validated and applied using a novel peptide immunoaffinity liquid chromatography-tandem mass spectrometry (IA-LC-MS/MS) assay. This assay accurately quantifies dystrophin/mini-dystrophin in human and preclinical species with sufficient sensitivity for immediate application in preclinical/clinical trials.

GENE THERAPY (2022)

Review Biochemistry & Molecular Biology

Quantitative interactome analysis with chemical cross- linking and mass spectrometry

Helisa H. Wippel et al.

Summary: This article provides an overview of recent technological developments and applications of qXL-MS, including the design and synthesis of cross-linkers, development of new liquid chromatography-MS methodologies, and computational developments for data interpretation.

CURRENT OPINION IN CHEMICAL BIOLOGY (2022)

Article Clinical Neurology

Exon-Skipping in Duchenne Muscular Dystrophy

Shin’ichi Takeda et al.

Journal of Neuromuscular Diseases (2021)

Review Pharmacology & Pharmacy

Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies

Omar Sheikh et al.

Summary: Currently, steroids are the most commonly used medication for DMD patients, while stop codon readthrough, gene replacement, and exon skipping therapies aim to restore dystrophin expression. Among these strategies, gene replacement therapy has gained recent momentum, and exon-skipping continues to be popular. FDA approval of three exon-skipping antisense oligonucleotides demonstrates regulatory progress, but controversy remains regarding the effectiveness and design of eteplirsen. Cell-penetrating peptides show promise in treating DMD-related cardiomyopathy but pose regulatory challenges.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Review Biotechnology & Applied Microbiology

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Jerry R. Mendell et al.

Summary: Hereditary diseases are caused by gene mutations, affecting millions of Americans, and gene therapy using adeno-associated virus (AAV) has shown promise in treating these diseases. Five treatments have been approved for commercialization, with many more in clinical trials, showcasing the potential of gene therapy in treating a wide range of genetic disorders.

MOLECULAR THERAPY (2021)

Article Clinical Neurology

Temporal Proteomic Profiling During Differentiation of Normal and Dystrophin-Deficient Human Muscle Cells

Mansi Goswami et al.

Summary: Time series proteome profiling using the super SILAC strategy can effectively assess temporal changes in protein expression during myogenesis and define downstream consequences of dystrophin deficiency on these temporal protein expressions. Key alterations were identified in dystrophin-deficient myoblast differentiation compared to normal myoblasts, indicating potential attractive therapeutic targets.

JOURNAL OF NEUROMUSCULAR DISEASES (2021)

Article Clinical Neurology

Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy

James S. Novak et al.

Journal of Neuromuscular Diseases (2021)

Article Clinical Neurology

Congenital muscular dystrophies: What is new?

Alberto A. Zambon et al.

Summary: Congenital muscular dystrophies are a group of inherited conditions characterized by muscle weakness before ambulation, delayed motor milestones, and dystrophic muscle pathology. Multiple genes, at least 35, are responsible for CMD phenotypes, leading to a wide spectrum of clinical manifestations. Recent advances in gene discovery have expanded the understanding of CMDs, with comprehensive gene panels able to provide a final diagnosis in around 60% of cases.

NEUROMUSCULAR DISORDERS (2021)

Review Biochemistry & Molecular Biology

The Dystrophin Node as Integrator of Cytoskeletal Organization, Lateral Force Transmission, Fiber Stability and Cellular Signaling in Skeletal Muscle

Paul Dowling et al.

Summary: This passage discusses the role of the protein product of the DMD gene, dystrophin, in Duchenne muscular dystrophy, as well as its interaction with other proteins in muscle cells. It also highlights the central role of the dystrophin complex in muscle fibers in integrating cytoskeletal organization and cellular signaling at the muscle periphery.

PROTEOMES (2021)

Article Biochemical Research Methods

Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM)

Emily H. Canessa et al.

JOURNAL OF MASS SPECTROMETRY (2020)

Article Medicine, Research & Experimental

Orthogonal analysis of dystrophin protein and mRNA as a surrogate outcome for drug development

Kitipong Uaesoontrachoon et al.

BIOMARKERS IN MEDICINE (2019)

Article Clinical Neurology

Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology

Annemieke Aartsma-Rus et al.

JOURNAL OF NEUROMUSCULAR DISEASES (2019)

Article Biochemical Research Methods

Chemical cross-linking in the structural analysis of protein assemblies

Feixia Chu et al.

METHODS (2018)

Article Multidisciplinary Sciences

Muscle MRI and functional outcome measures in Becker muscular dystrophy

Andrea Barp et al.

SCIENTIFIC REPORTS (2017)

Review Biochemistry & Molecular Biology

The biochemical and mass spectrometric profiling of the dystrophin complexome from skeletal muscle

Sandra Murphy et al.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)

Article Genetics & Heredity

A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East China

Xihua Li et al.

ORPHANET JOURNAL OF RARE DISEASES (2015)

Review Biochemistry & Molecular Biology

Dystrophin complex functions as a scaffold for signalling proteins

Bruno Constantin

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2014)

Article Clinical Neurology

Dystrophin levels and clinical severity in Becker muscular dystrophy patients

J. C. van den Bergen et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)

Article Clinical Neurology

Dystrophin quantification Biological and translational research implications

Karen Anthony et al.

NEUROLOGY (2014)

Article Clinical Neurology

Eteplirsen for the Treatment of Duchenne Muscular Dystrophy

Jerry R. Mendell et al.

ANNALS OF NEUROLOGY (2013)

Review Biochemistry & Molecular Biology

Proteomics of the Dystrophin-glycoprotein Complex and Dystrophinopathy

Ashling Holland et al.

CURRENT PROTEIN & PEPTIDE SCIENCE (2013)

Article Multidisciplinary Sciences

Identification of New Dystroglycan Complexes in Skeletal Muscle

Eric K. Johnson et al.

PLOS ONE (2013)

Article Biochemistry & Molecular Biology

Phosphorylation on threonine 11 of β-dystrobrevin alters its interaction with kinesin heavy chain

Federica Fratini et al.

FEBS JOURNAL (2012)

Article Biochemistry & Molecular Biology

Glycoproteomic characterization of recombinant mouse α-dystroglycan

Rebecca Harrison et al.

GLYCOBIOLOGY (2012)

Article Multidisciplinary Sciences

Proteomic Analysis Reveals New Cardiac-Specific Dystrophin-Associated Proteins

Eric K. Johnson et al.

PLOS ONE (2012)

Article Biochemistry & Molecular Biology

Site Mapping and Characterization of O-Glycan Structures on α-Dystroglycan Isolated from Rabbit Skeletal Muscle

Stephanie H. Stalnaker et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2010)

Article Multidisciplinary Sciences

O-Mannosyl Phosphorylation of Alpha-Dystroglycan Is Required for Laminin Binding

Takako Yoshida-Moriguchi et al.

SCIENCE (2010)

Article Medicine, Research & Experimental

Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy

Yukiko K. Hayashi et al.

JOURNAL OF CLINICAL INVESTIGATION (2009)

Review Clinical Neurology

Dystrophin and mutations: one gene, several proteins, multiple phenotypes

F Muntoni et al.

LANCET NEUROLOGY (2003)

Review Biochemistry & Molecular Biology

The complexities of dystroglycan

SJ Winder

TRENDS IN BIOCHEMICAL SCIENCES (2001)